Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, J. -H. | - |
dc.contributor.author | Yhim, H. -Y. | - |
dc.contributor.author | Kwak, J. -Y. | - |
dc.contributor.author | Ahn, J. -S. | - |
dc.contributor.author | Yang, D. -H. | - |
dc.contributor.author | Lee, J. -J. | - |
dc.contributor.author | Kim, S. -J. | - |
dc.contributor.author | Kim, J. -S. | - |
dc.contributor.author | Park, S. J. | - |
dc.contributor.author | Choi, C. W. | - |
dc.contributor.author | Eom, H. -S. | - |
dc.contributor.author | Park, S. -K. | - |
dc.contributor.author | Choi, S. -Y. | - |
dc.contributor.author | Kim, S. -H. | - |
dc.contributor.author | Kim, D. -W. | - |
dc.contributor.author | Lee, S. | - |
dc.date.accessioned | 2021-08-11T17:44:10Z | - |
dc.date.available | 2021-08-11T17:44:10Z | - |
dc.date.issued | 2016-06 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.issn | 1569-8041 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/9106 | - |
dc.description.abstract | Background: The use of imatinib combined with chemotherapy has demonstrated improved outcome in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL). However, a substantial proportion of patients continue to die as a result of disease progression. We assessed the minimal residual disease (MRD)-based effect and long-term outcome of first-line incorporation of dasatinib (100 mg once daily) into chemotherapy alternatively for adults with Ph-positive ALL. The primary end point was the major molecular response (MMR) rate by the end of the second dasatinib cycle. Patients with a donor proceeded to allogeneic stem cell transplantation (SCT) as early as possible. MRD monitoring was centrally evaluated by real-time quantitative polymerase chain reaction (4.5-log sensitivity) using bone marrow samples. Fifty-one patients (median age, 46 years) were enrolled and treated with this strategy. After the first dasatinib cycle, 50 patients (98.0%) achieved complete remission (CR). By the end of the second dasatinib cycle, 46 (93.9%) of 49 assessable patients had persistent CR, and 38 (77.6%) had MMR (32.7%) or undetectable MRD (44.9%). On the basis of the MRD kinetics by this time point, the numbers of early-stable, late, and poor molecular responders were 23 (46.9%), 15 (30.7%), and 11 (22.4%), respectively. Thirty-nine patients (76.5%) underwent allogeneic SCT in CR1. After a median follow-up of 54 months, the 4-year cumulative incidence of relapse and disease-free survival (DFS) rate for all patients were 30.0% and 52.0%, respectively, and the corresponding outcomes among those receiving allogeneic SCT in CR1 were 20.5% and 64.1%, respectively. Poor molecular responders had a higher risk of relapse and DFS than those of early-stable molecular responders. This dasatinib-based protocol was effective for achieving a good quality molecular response and durable DFS in adults with Ph-positive ALL. clinicaltrials.gov, NCT01004497. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Oxford University Press | - |
dc.title | Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1093/annonc/mdw123 | - |
dc.identifier.scopusid | 2-s2.0-84974777815 | - |
dc.identifier.wosid | 000377427900018 | - |
dc.identifier.bibliographicCitation | Annals of Oncology, v.27, no.6, pp 1081 - 1088 | - |
dc.citation.title | Annals of Oncology | - |
dc.citation.volume | 27 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1081 | - |
dc.citation.endPage | 1088 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | IMATINIB-RESISTANT | - |
dc.subject.keywordPlus | HYPER-CVAD | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | TRANSPLANTATION | - |
dc.subject.keywordPlus | PHASE-2 | - |
dc.subject.keywordAuthor | minimal residual disease | - |
dc.subject.keywordAuthor | dasatinib | - |
dc.subject.keywordAuthor | Philadelphia chromosome | - |
dc.subject.keywordAuthor | acute lymphoblastic leukemia | - |
dc.subject.keywordAuthor | allogeneic stem cell transplantation | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.